Malignant tumors of the female reproductive system
Conditions
Interventions
Observation group:None
Sponsors
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. 18 years of age and above 2. Newly diagnosed stage III or IV CC or EC 3. Completed initial conventional therapy (including at least chemotherapy, radiotherapy, or chemoradiotherapy) between December 2022 and December 2024, with treatment administered within 6 months of diagnosis. 4. Be told by your doctor that your condition is stable 5. Patients must sign the study informed consent form
Exclusion criteria
Exclusion criteria: 1. Prior treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 targeted biologic therapy or another drug that stimulates or co-inhibits the T cell receptor 2. Previous participation or ongoing participation in clinical trials 3. Patients receiving another line of therapy after initial treatment 4. Inability or unwillingness to provide informed consent 5. Not fluent in language 6. Expressing or exhibiting hearing difficulties that would make conversation challenging
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment decision making;Unmet needs and gaps from diagnosis to post-treatment surveillance;Initial treatment experiences; | — |
Countries
China
Contacts
Public ContactGang Chen
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology / Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed